Finland· FI-REL-REL4714

Nefadar

A nefazodone product containing nefazodone hydrochloride, registered in Finland by Bristol-Myers Squibb Ab. The same ATC class is registered in 4 of our 19 countries.

ATC N06AX06

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedNefadarATCN06AX06REGISTER NO.FI-REL-REL4714PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Nefazodone is registered in 4 of 19 countries.

Countries holding a registration under ATC N06AX06 (nefazodone), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 3 of them publish a price we can compare per daily dose

Nefazodone · ATC N06AX06

4 / 19 countries

  • Finlandprice
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Nefazodone hydrochloride
Manufacturer
Bristol-Myers Squibb Ab
Country
Finland (FI)
ATC code
N06AX06
ATC class
Nefazodone
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

410 interactions on record for nefazodone.

Graded by severity as the source publishes them — 144 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nefazodone · interactions on record

410 records

  • 144 severe
  • 215 moderate
  • 8 minor
  • 42 info

Most severe, free to view

  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nefazodone in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nefazodone products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fb83c929-43ed-4241-9f6f-3b8d8ae4f34b
GET /v1/drugs/fb83c929-43ed-4241-9f6f-3b8d8ae4f34b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.4",
  "form": "tabletti",
  "route": null,
  "ddd_unit": "g",
  "strength": "300 mg",
  "atc_label": "nefatsodoni",
  "ma_number": "12559",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL4714",
  "authorised_at": "1997-10-06"
}

See everything about nefazodone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.